Drug Profile
LY 2780301
Alternative Names: LY S6KAKT1; LY-2780301Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Institut Paoli-Calmettes; Institute Gustave-Roussy
- Class Antineoplastics
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in France (PO)
- 08 Sep 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)
- 08 Sep 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France (PO)